Proteomics International PromarkerD predictive test for diabetic kidney disease

Proteomics International Laboratories has launched its first-in-class predictive test for diabetic kidney disease, PromarkerD, in Australia. By enabling proactive management, the company aims to reduce the personal and financial costs associated with what is a life-threatening condition.

The product is a clinically validated blood test that can predict the risk of developing chronic kidney disease in type 2 diabetes patients up to four years before clinical symptoms appear. This early warning provides healthcare professionals with a critical window to intervene, which should enable better patient management and reduce the risk of severe kidney complications, including kidney failure and the need for dialysis or transplant.

The test will initially be available through referral by a healthcare professional in Western Australia and the Northern Territory, before it is made available nationwide.